Voters Are Ahead of Politicians on Drug Pricing — And They Want Patent Reform
How Celgene and Bristol Myers Squibb Used Volume Restrictions to Delay Revlimid Competition
Investigating the pharmaceutical industry’s drug patenting practices
The Year in Patent Reform
Our New Study: The Burden of Patent Thickets
I-MAK’s Quest To Trim The Biopharmaceutical Patent Thicket
The Next Pandemic with Priti Krishtel and Tahir Amin
Big Pharma fights patent disclosure demand from investors
Big Pharma’s Patent Abuses Are Fueling the Drug Pricing Crisis
Patent reform and lower drug prices should be bipartisan priorities